Fig. 2From: The SYGMA programme of phase 3 trials to evaluate the efficacy and safety of budesonide/formoterol given ‘as needed’ in mild asthma: study protocols for two randomised controlled trialsSYGMA2 study design. bid twice daily, E enrolment, FU follow-up phone call, TUM Turbuhaler® Usage Monitor, recording use of each blinded study inhalers. †Corresponds to the terbutaline Turbuhaler® 0.4 mg, with regards to the dose deliveredBack to article page